Plus: Jeffrey Sevigny named CMO of Rapport, and updates from Garuda, Metis, Ovid and more

Plus: CureVac hires Axel Malkomes as CFO; new CEOs at Coya, Libra; and updates from 4BIO, Memo and Alltrna

Plus: Chemify hires CBO to realize commercial ambitions and more from Biocartis and Estrella

Plus: Fresenius and NS Pharma name new presidents, and updates from The Francis Crick Institute, CIRM, Nuvalent and more

Plus: Iaso gets full rights to Fucaso from Innovent, and updates from Genexine, EPD, Pentixapharm and Glycotope

Vaccine developer also cutting 30% of staff, adding years of cash runway

Plus: Ramanayake joins CureVac and updates from Oruka, Madrigal and AusBiotech

Plus: Carmot spinout Kimia raises $55M series A round, CureVac tumbles on loss in patent case and more from Lassen, Atavistik, Crinetics, Merck and CSL

Plus: CureVac’s Splawski lands at Yarrow and updates from Genelux, Cour and more

Plus: Haas becomes CEO at LimmaTech, and updates from Sagimet, Agenus, Triumvira and Passage Bio